Food Kansas City Royals and DrugAdministration FDA the

Food clarifies baseball tickets and DrugAdministration interprets (FDA), the commercialization of MelaFind(R), and forgeneral corporate purposes, including working capital.All of the shares of common stock are being offered pursuant to a shelfregistration statement previously filed with the Securities and ExchangeCommission (the "SEC") which was declared effective on July 7, 2008.Needham & Company, LLC served as the lead placement agent and Oppenheimer& Co Inc. served as the co-placement agent for the offering.This press release does not constitute an offer to sell or thesolicitation of an offer to buy any securities in this offering. Thereshall not be any sale of these securities in any state or jurisdiction inwhich such offering, sale or solicitation would be unlawful prior toregistration or qualification under the securities laws of any such stateor jurisdiction. The shares of common stock may only be offered by meansof a prospectus. Copies of the final prospectus supplement andaccompanying base prospectus can be obtained at the SEC's website at http:// or from EOS by writing or calling EOS at 3 West MainStreet, Suite 201, Irvington, NY 10533, (914) 591-3783.About Electro-Optical SciencesElectro-Optical Sciences is a medical technology company focused ondeveloping MelaFind(R), a non-invasive and objective computer visionsystem intended to aid in the early detection of melanoma. EOS designedMelaFind(R) to assist in the evaluation of pigmented skin lesions,including atypical moles, which have one or more clinical or historicalcharacteristics of melanoma, before a final decision to biopsy has beenrendered.

MelaFind(R) acquires and displays multi-spectral (from blue tonear infrared) digital images of pigmented skin lesions and uses automaticimage analysis and statistical pattern recognition to help identifylesions to be considered for biopsy to rule out melanoma.On June 4, 2009 EOS announced the submission of its PMA application forMelaFind(R) to the FDA cubs rooftop . Although the application is subject to the FDA'sexpedited review procedures, EOS cannot predict either the timing of theFDA's decision on the PMA application nor the outcome . The FDA approval ofMelaFind(R) is required prior to marketing in the United States.For more information on EOS, visit HarborThis press release includes "forward-looking statements" within themeaning of the Securities Litigation Reform Act of 1995 . These statementsinclude but are not limited to our plans, objectives, expectations andintentions and other statements that contain words such as "expects,""contemplates," "anticipates," "plans," "intends," "believes" andvariations of such words or similar expressions that predict or indicatefuture events or trends, or that do not relate to historical matters.These statements are based on our current beliefs or expectations and areinherently subject to significant uncertainties and changes incircumstances, many of which are beyond our control .

There can be noassurance that our beliefs or expectations will be achieved kansas city royals . Actualresults may differ materially from our beliefs or expectations due toeconomic, business, competitive, market and regulatory factors.For further information contact:David CareyLazar Partners Ltd.212-867-1768Email ContactCopyright 2009, Market Wire, All rights reserved.-0- . HEBRON, KY, Jul 17 (MARKET WIRE) -- BlueStar, the leading innovator in solutions-based distribution for AutoID, Point-of-Sale, Mobility, and RFID products, today announced thatBlueStar Canada has been appointed as an authorized service center forall Datamax-O'Neil printers . The new service center makes BlueStar Canadathe only authorized service provider in Canada for Datamax-O'Neil'sextensive product lines.Under sophisticated tech service protocols, the BlueStar Canada TechnicalServices Department provides comprehensive support for the full range ofDatamax-O'Neil printers . Customers can send their printers directly toBlueStar Canada, as opposed to Datamax-O'Neil's U.S service centers inOrlando, Florida and El Paso, Texas.